News | September 28, 2021
Bal Pharma ramps up API capacity of Gliclazide
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
In terms of volume, the company commands a market share 25 per cent globally for Gliclazide, as per the IQVIA report
The order strengthens the company’s position in the East African market
These were the findings of the Post Marketing Surveillance (PMS), study of Favipiravir (FabiFlu) on over 1000 patients
The division will focus on products that are required during ophthalmic surgical procedures like cataracts and refractive surgeries among others
First participants enrolled in Phase 1 clinical trial of combination NanoFlu/NVX-CoV2373 vaccine with Matrix-M adjuvant. The Phase 1/2 study will also evaluate immunogenicity and safety
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
The revenues and profits derived from the new subsidiary will be consolidated in the parent company
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Subscribe To Our Newsletter & Stay Updated
